WCLC 2019 – 5-year survival in advanced NSCLC: greater than 4-fold increase with nivolumab over docetaxel


  • Cristina Ferrario — Agenzia Zoe
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with previously treated non-small cell lung cancer (NSCLC), 5-years overall survival (OS) rates increased more than 4-fold after treatment with the PD-1 inhibitor nivolumab compared to docetaxel.
  •  No new safety signals emerged for nivolumab in the long-term and the drug remained well-tolerated.

Why this matters

  • Historically, survival outcomes for advanced NSCLC have been poor.
  • 5-years outcomes from CheckMate 017 and 057 represent the longest survival follow-up for randomized phase 3 trials of an immune checkpoint inhibitor in this population.  

Study design

  • CheckMate 017 and CheckMate 057 randomized phase 3 trials included patients with, respectively, squamous and non-squamous previously treated advanced NSCLC.
  • In the pooled analysis (CheckMate 017/057), 854 patients with ECOG performance status (PS) ≤ 1, progressing during or after first-line platinum-based chemotherapy were included.
  • Patients were randomized to nivolumab 3 mg/kg q2w or docetaxel 75 mg/m2 q3w until progression or unacceptable toxicity.
  • OS was the primary endpoint for the two studies; additional endpoints included progression-free survival (PFS), objective response rate (ORR), efficacy by tumour PD-L1 expression, safety, PROs.

Key results

  • Survival benefits were still evident for nivolumab vs docetaxel in the long-term pooled analysis, with 5-year OS rates 13.4% vs 2.6% (HR 0.68).
  • OS benefit with nivolumab vs docetaxel was observed across subgroups of patients.
  • The 5-years pooled PFS rate was 8% with nivolumab and 0% with docetaxel.
  • The chance of remaining progression-free at 5 years was 60% and 78% in patients without progression at 2 and 3 years, respectively, after treatment with nivolumab.
  • ORR was 19.7% for nivolumab and 11.2% for docetaxel.
  • At 5 years, 10% of survivors in nivolumab group were off study drug, progression-free and with no subsequent therapy vs 0% in the docetaxel group.
  • No evidence of grade 3-4 treatment-related adverse events (AE) and no new safety signals emerged for nivolumab with a minimum follow-up of 5 years.

Funding

  • Bristol-Myers Squibb.

Expert commentary

“It is interesting to note that, following platinum-based chemotherapy, nivolumab has shown survival benefits across all PD-L1 subsets, including the PD-L1 negative (